TriangleVenetoclax Plus CLAG-M (NCT04797767)
Venetoclax Plus CLAG-M trial for Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (NCT04797767). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for acute myeloid leukemia and other high grade myeloid neoplasms, in adults.
The idea: add venetoclax to a chemotherapy combination called CLAG M. Venetoclax may stop the growth of cancer cells by blocking Bcl 2, a protein needed for cancer cell survival. AbbVie is listed as a collaborator.
This single center phase 1 and 2 trial plans 62 patients. The first questions are the best dose and side effects. At Fred Hutch in Seattle, Mary-Beth Percival leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.